168 related articles for article (PubMed ID: 18615399)
1. [131I-MIBG therapy in the treatment of pheochromocytoma in children--own experiences].
Hasse-Lazar K; Krajewska J; Paliczka-Cieślik E; Jurecka-Lubieniecka B; Michalik B; Handkiewicz-Junak D; Roskosz J; Jarzab B
Endokrynol Pol; 2008; 59(3):235-40. PubMed ID: 18615399
[TBL] [Abstract][Full Text] [Related]
2. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
[TBL] [Abstract][Full Text] [Related]
3. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma.
Rose B; Matthay KK; Price D; Huberty J; Klencke B; Norton JA; Fitzgerald PA
Cancer; 2003 Jul; 98(2):239-48. PubMed ID: 12872341
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic effectiveness of 131I-MIBG on malignant pheochromocytoma--results of long-term follow-up].
Kusakabe K; Kanaya K; Kanaya S; Yazaki E; Nakano K; Matsumoto N; Kobayashi H; Maki M; Itou Y; Obara T
Kaku Igaku; 1994 Dec; 31(12):1495-502. PubMed ID: 7861648
[TBL] [Abstract][Full Text] [Related]
5. Nuclear medicine therapy of pheochromocytoma and paraganglioma.
Troncone L; Rufini V
Q J Nucl Med; 1999 Dec; 43(4):344-55. PubMed ID: 10731785
[TBL] [Abstract][Full Text] [Related]
6. Proteinuria in metastatic pheochromocytoma is associated with an increased risk of Acute Respiratory Distress Syndrome, spontaneously or after therapy with 131I-meta-iodobenzylguanidine (131I-MIBG).
Porzig A; Matthay KK; Dubois S; Pampaloni M; Damon L; Hawkins R; Goldsby R; Hollinger F; Fitzgerald P
Horm Metab Res; 2012 Jun; 44(7):539-42. PubMed ID: 22588707
[TBL] [Abstract][Full Text] [Related]
7. External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG.
Fishbein L; Bonner L; Torigian DA; Nathanson KL; Cohen DL; Pryma D; Cengel KA
Horm Metab Res; 2012 May; 44(5):405-10. PubMed ID: 22566196
[TBL] [Abstract][Full Text] [Related]
8. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ;
Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026
[TBL] [Abstract][Full Text] [Related]
9. Repeated [131I]metaiodobenzylguanidine therapy in two patients with malignant pheochromocytoma.
Lam MG; Lips CJ; Jager PL; Dullaart RP; Lentjes EG; van Rijk PP; de Klerk JM
J Clin Endocrinol Metab; 2005 Oct; 90(10):5888-95. PubMed ID: 16046591
[TBL] [Abstract][Full Text] [Related]
10. Management of malignant phaeochromocytoma: a retrospective review of the use of MIBG and chemotherapy in the West Midlands.
Hartley A; Spooner D; Brunt AM
Clin Oncol (R Coll Radiol); 2001; 13(5):361-6. PubMed ID: 11716230
[TBL] [Abstract][Full Text] [Related]
11. [A case of malignant pheochromocytoma treated with 131I-metaiodobenzylguanidine and CVD regimen].
Ukimura O; Kojima M; Hosoi S; Itoh H; Watanabe H; Minamikawa T
Nihon Hinyokika Gakkai Zasshi; 1994 May; 85(5):811-4. PubMed ID: 8022145
[TBL] [Abstract][Full Text] [Related]
12. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.
Loh KC; Fitzgerald PA; Matthay KK; Yeo PP; Price DC
J Endocrinol Invest; 1997 Dec; 20(11):648-58. PubMed ID: 9492103
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic possibilities in metastatic pheochromocytoma].
Vierhapper H; Raber W
Zentralbl Chir; 1997; 122(6):494-7. PubMed ID: 9334119
[TBL] [Abstract][Full Text] [Related]
14. Use of m-[131I]iodobenzylguanidine in the treatment of malignant pheochromocytoma.
Krempf M; Lumbroso J; Mornex R; Brendel AJ; Wemeau JL; Delisle MJ; Aubert B; Carpentier P; Fleury-Goyon MC; Gibold C
J Clin Endocrinol Metab; 1991 Feb; 72(2):455-61. PubMed ID: 1991814
[TBL] [Abstract][Full Text] [Related]
15. Complete remission of metastatic pheochromocytoma in
Sugino T; Ando R; Unno R; Iida K; Naiki T; Hamamoto S; Mizuno K; Okada A; Umemoto Y; Kawai N; Tozawa K; Hayashi Y; Inaki A; Kayano D; Kinuya S; Yasui T
BMC Res Notes; 2017 Dec; 10(1):750. PubMed ID: 29258609
[TBL] [Abstract][Full Text] [Related]
16. Clinical review: Current treatment of malignant pheochromocytoma.
Scholz T; Eisenhofer G; Pacak K; Dralle H; Lehnert H
J Clin Endocrinol Metab; 2007 Apr; 92(4):1217-25. PubMed ID: 17284633
[TBL] [Abstract][Full Text] [Related]
17. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
[TBL] [Abstract][Full Text] [Related]
18. 131I-metaiodobenzylguanidine therapy for malignant pheochromocytoma.
Sakahara H; Endo K; Saga T; Hosono M; Kobayashi H; Konishi J
Ann Nucl Med; 1994 May; 8(2):133-7. PubMed ID: 7521194
[TBL] [Abstract][Full Text] [Related]
19. Radiation dosimetry, pharmacokinetics, and safety of ultratrace Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid.
Coleman RE; Stubbs JB; Barrett JA; de la Guardia M; Lafrance N; Babich JW
Cancer Biother Radiopharm; 2009 Aug; 24(4):469-75. PubMed ID: 19694582
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.
Gonias S; Goldsby R; Matthay KK; Hawkins R; Price D; Huberty J; Damon L; Linker C; Sznewajs A; Shiboski S; Fitzgerald P
J Clin Oncol; 2009 Sep; 27(25):4162-8. PubMed ID: 19636009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
